Highlights from

European Crohn’s and Colitis Organisation

Congress 2018

Vienna 14-17 February 2018

Integration of “omics” and potential for clinical practice

“Omics” have accelerated drug discovery for clinical practice and are therefore promising elements in optimising IBD treatment [22]. They can be used for each of the four basic components in IBD pathogenesis (Table 3).

Table 3: Basic components of IBD and their treatment strategies [24]

ECCO-2018-Table-3

Omics-based biomarkers for clinical practice are able to detect subtypes (molecular signatures). Thus, they suit a holistic view of the patient integrating the person, the affected organ, its lesion, as well as cell and molecular structures [23,34].

  1. Kralyevic S, et al. EMBO Rep. 2004;5:837-42.
  2. Stylianou DE. Mol Diagn Ther. 2018;22:11-23.
  3. Fiocchi C, et al. ECCO 2018.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.